Send by American Banking News

of Bristol-Myers (NYSE :BMY) from “Buy” to “hold” in a research note to investors on Tuesday, citing increased expectations for apixaban and ipilimumab. [...]

28 Jul 2010 Ipilimumab (BMS734016; MDX 101; MDX-010; MDX-CTLA-4; MDX-CTLA4) is an anti-CTLA-4 monoclonal antibody, which is in development by Medarex [...]

9 Jun 2010 Ipilimumab targets CTLA-4 (cytotoxic T-lymphocyte associated antigen 4), which is the best-known of the "checkpoint molecules" that have [...]

Send by bw

Ipilimumab is one of a class of drugs called monoclonal antibodies, which stimulate the body's own immune system to fight disease. The experimental treatment is being developed by Bristol-Myers Squibb and Medarex, a US biotech company. [...]

Researchers' next challenge is to prove ipilimumab's superiority to chemo in phase 3 trials and hopefully they can identify biomarkers to identify or predict melanoma patients whom will respond to these CTLA-4 agents. [...]

Ipilimumab, a monoclonal antibody designed to promote anti-tumour immunity, increases survival by about three and a half months in metastatic melanoma compared to a therapeutic vaccine used as a control. Median survival in patients with [...]

Review: Anti–CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events Ipilimumab (MDX-010) is a fully human, monoclonal antibody that [...]

Medarex, Inc. today announced interim results from a Phase 1 2 trial of ipilimumab, an investigational oncology immunotherapy, as monotherapy or in combination. [...]

Send by Dr. NICK

August 19, 2010 — Bristol-Myers Squibb (BMS) has announced that its Biologics License Application for ipilimumab for metastatic melanoma has been accepted for filing by the US Food and Drug Administration (FDA) and that it has been [...]

Bristol-Myers has asked the FDA to approve ipilimumab for patients with advanced melanoma, the deadliest form of skin cancer. Bristol-Myers said the FDA is taking additional time to review new data about the drug's use in pre-treated [...]

Phase III trial results for ipilimumab, an immunomodulatory monoclonal antibody that targets cytotoxic T-lymphocyte antigen 4 (CTLA4), showed that it increased survival by 3.7 months in patients with advanced melanoma (N. Engl. J. Med. [...]

Send by Patrick Yachimski, MD, Assista

While the endoscopic and histopathologic findings are not specific, the timing of onset following ipilimumab infusion is consistent with an acute autoimmune colitis related to CTLA4 therapy. Case series have described acute colitis in [...]

Send by David Gurevich

Ipilimumab is a new treatment for advanced melanoma that has generated a lot of excitement. While a step in the right direction, it has limited efficacy and still has to be determined as to its best use. [...]

Send by Dr. John MD

Ipilimumab aids the activation of the immune system's T-cells in order to fight the cancer. The results of a study that analyze the effects of the drug on advanced melanoma patients are very impressive: [...]

Study Meets Primary Endpoint of Overall Survival for Patients Treated with Ipilimumab (Hazard Ratio = 0.66 – 0.68) Forty-four to 46 Percent of Patients Treated with Ipilimumab Alive at One Year and Read more [...]

Send by www.businesswire.com

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Announces that the U.S. Food and Drug Administration Has Extended the Review Timeline for the Ipilimumab Biologics License Application [...]

Ipilimumab may improve survival in patients with previously treated metastatic melanoma, but with risk of severe adverse events, according to research published in the Aug. 19 issue of the New England Journal of Medicine. [...]

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun. 2010;10:9 Authors: Wolchok JD, Weber JS, Hamid O, Lebbé C, Maio M, Schadendorf D, de Pril V, [...]

Send by AntonioCaperna

Ipilimumab, a fully human monoclonal antibody against cytotoxic T-lymphocyte antigen-4, has demonstrated clinical activity against advanced melanoma. In prior studies, gp100 vaccine showed immunological and clinical responses, [...]

CBS, New York, September 14, 2010 This is a general announcement about the drug, ipilimumab. It relates stories of two patients in the trial who have the side effect of hair turning white as a result of the drug shutting down the production of melanin. It is a side effect very much desired in any pa [...]

The US Food and Drug Administration has accepted, for filing and review, drug major Bristol-Myers Squibb's (NYSE: BMY) Biologics License Application for ipilimumab for the treatment of adult patients with advanced melanoma who have been [...]

Ipilimumab may improve survival in patients previously treated for metastatic melanoma but it does have risk of serious side effects. Doctors at the Dana Farber Cancer Center reviewed data from 676 patients with advanced melanoma. [...]

Send by Armen Hareyan

Ipilimumab is a human monoclonal antibody that targets a key negative regulator (CTLA-4) of the body's immune response against tumor cells. By relieving negative regulation, this antibody effectively takes a foot off the brake of the [...]

Subjects receiving ipilimumab on single-patient INDs are eligible for this study provided that the single-patient IND is closed and the subject meets all other eligibility requirements for this study. If a subject is eligible for a [...]

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the US Food and Drug Administration (FDA) has accepted, for filing and review, the Biologics License Application (BLA) for ipilimumab for the treatment of adult patients with [...]